SCHEMBL24849057

SCHEMBL24849057

COC(=O)c1cc(Cc2ccnc(NCc3ccc(OC)cc3OC)c2F)ncc1Nc1ccc(S(C)(C)C)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ KDM4C Q9H3R0 1/20 0.40
▸ CYP1A2 P05177 12/20 0.36
▸ CYP3A4 P08684 12/20 0.36
▸ CYP2C19 P33261 12/20 0.36
▸ CYP2D6 P10635 11/20 0.36
▸ CLK4 Q9HAZ1 6/20 0.36
▸ CYP2C9 P11712 4/20 0.36
▸ HSD17B10 Q99714 5/20 0.35
▸ MAPK1 P28482 5/20 0.35
▸ USP2 O75604 8/20 0.34
▸ TSHR P16473 8/20 0.34
▸ ALDH1A1 P00352 6/20 0.34
▸ LMNA P02545 4/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HIF1A Q16665 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24849056 0.89 MAPT (0.42) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL31236928 0.89 MAPT (0.42) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL27224637 0.83 KDM4C (0.46) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL24849644 0.81 NUDT1 (0.33) KMT2A
SCHEMBL31401592 0.79 MAPT (0.44) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL38651248 0.79 MAPT (0.44) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL31401688 0.77 CYP1A2 (0.44) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL23694114 0.77 MAPT (0.43) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL31401828 0.77 MAPT (0.43) MAPTKDM4CCYP1A2CYP3A4CYP2C19
SCHEMBL23694115 0.76 MAP2K1 (0.43) MAPTKDM4CERBB2PRKACARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-31 — — US disclosed
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE BRAF, NRAS, KRAS MAPT 1620/4885KDM4C 777/4885CYP1A2 2143/4885
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, NRAS, KRAS MAPT 4690/4885KDM4C 1698/4885CYP1A2 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback